Change in number of shares in BrainCool AB (publ)
Conversion of convertible notes into shares, as part of the financing agreements announced 24 August and 5 November, 2018.
The number of convertible notes converted on February 27, was 9. The number of convertible notes remaining under the second tranche for future conversion is 0. The number of convertible notes remaining under the third tranche is 43. The number of shares and the number of votes before the conversion was 38 388 342. Through this conversion, and once the shares from the conversion will be registered at Bolagsverket, the number of shares and the number of votes shall have increased by 138 461. The total number of shares and total number of votes after this conversion and once the shares have been registered at Bolagsverket will amount to 38 526 803.
Conversion price is 6,50 SEK per share and conversion amount is 900 000 SEK.
For terms and conditions of the convertible notes, please visit:
*In the English version of the press release from January 31, 2019, it was stated that the number of convertible notes remaining under the first tranche for future conversion was 2. The correct reference is the second tranche, as the first tranche was already fully converted on January 21, 2019.
This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on February 28, 2019.
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
About BrainCool AB (publ)
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.